[8-K] Blueprint Medicines Corporation Reports Material Event

Rhea-AI Filing Summary

On 18 June 2025, Blueprint Medicines Corporation (Nasdaq: BPMC) reported the results of its 2025 Annual Meeting of Stockholders (Form 8-K, Item 5.07).

• Board elections: Class I directors Jeffrey W. Albers (44,683,223 for / 15,507,415 withheld ≈ 74%), Mark Goldberg, M.D. (46,734,594 / 13,456,044 ≈ 78%), and John Tsai, M.D. (47,572,890 / 12,617,748 ≈ 79%) were elected to three-year terms ending at the 2028 meeting.
• Say-on-pay: Executive compensation received strong support, passing with 57,714,069 votes for (≈96%), 2,450,825 against, and 25,744 abstentions.
• Auditor ratification: Ernst & Young LLP was re-appointed as independent auditor for FY 2025 with 62,209,853 votes for (≈99.5%), 288,580 against, and 34,861 abstentions.

No additional matters were presented. The filing is routine, reflecting continued shareholder endorsement of management and governance practices without introducing new strategic or financial information.

Insights

Corporate Governance Analyst

TL;DR: Routine annual-meeting items passed comfortably; signals shareholder support but provides no new strategic insight.

The decisive approval of all proposals indicates stable governance and limited shareholder dissent. Director election support in the mid-70% range is adequate, though not overwhelming. The near-unanimous 96% say-on-pay vote and 99% auditor ratification demonstrate confidence in executive compensation structures and financial oversight. However, because these actions are standard for most public issuers and do not alter capital structure, operations, or guidance, they carry minimal direct valuation impact.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Understanding 8-K Material Events →

0001597264false00015972642025-06-182025-06-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 8-K

​

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 18, 2025

​

​

Blueprint Medicines Corporation

(Exact name of registrant as specified in its charter)

​

​

Delaware		001-37359		26-3632015
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

​

​ ​
45 Sidney Street Cambridge, Massachusetts		02139
(Address of principal executive offices)		(Zip Code)

​

 Registrant’s telephone number, including area code: (617) 374-7580

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	BPMC	Nasdaq Global Select Market

​

​

​

​

Item 5.07. Submission of Matters to a Vote of Security Holders.

​

Blueprint Medicines Corporation (the “Company”) held its Annual Meeting of Stockholders on June 18, 2025. The following is a summary of the matters voted on at that meeting:

​

1. The Company’s stockholders elected Jeffrey W. Albers, Mark Goldberg, M.D. and John Tsai, M.D. as Class I directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class I directors were as follows:

​

	​		​		​
​ Name	​	Votes For	​	Votes Withheld	​	Broker Non-Votes
Jeffery W. Albers	​	44,683,223	​	15,507,415	​	2,342,656
Mark Goldberg, M.D.	​	46,734,594	​	13,456,044	​	2,342,656
John Tsai, M.D.	​	47,572,890	​	12,617,748	​	2,342,656

​

2. The Company’s stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. The results of the stockholders’ non-binding, advisory vote with respect to compensation paid to the Company’s named executive officers were as follows:

​

	​		​		​
Votes For	​	Votes Against	​	Votes Abstaining	​	Broker Non-Votes
57,714,069	​	2,450,825	​	25,744	​	2,342,656

​

3. The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting for the fiscal year ending December 31, 2025. The results of the stockholders’ vote with respect to such ratification were as follows: 

​

	​		​
Votes For	​	Votes Against	​	Votes Abstaining
62,209,853	​	288,580	​	34,861

​

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.

​

​

2

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BLUEPRINT MEDICINES CORPORATION
Date: June 20, 2025	By:	/s/ Kathryn Haviland
		Kathryn Haviland
		Chief Executive Officer

​

​

​

​

​

​

​

3

​